The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer

被引:1
作者
Mallick, Sumit [1 ]
Duttaroy, Asim K. [2 ]
Dutta, Suman [3 ,4 ]
机构
[1] Yenepoya Deemed Univ, Stem Cells & Regenerat Med Ctr, Yenepoya Res Ctr, Univ Rd, Mangalore, Karnataka, India
[2] Univ Oslo, Inst Basic Med Sci, Fac Med, Dept Nutr, Oslo, Norway
[3] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, England
[4] Univ Oxford, Kavli Inst Nanosci Discovery, Dorothy Crowfoot Hodgkin Bldg, Oxford, England
来源
TRANSLATIONAL ONCOLOGY | 2024年 / 50卷
关键词
Triple negative breast cancer; Tumor tropism; PI3K; EMT; PI3K/AKT/mTOR pathway; Metastasis; Targeted therapy; PIK3CA MUTATIONS; GROWTH-FACTOR; PLUS FULVESTRANT; PI3K PATHWAY; PHASE-III; LANDSCAPE; INVASION; PLACEBO; INHIBITION; PACLITAXEL;
D O I
10.1016/j.tranon.2024.102140
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The PIK3CA gene is a linchpin in the intricate molecular network governing triple-negative breast cancer (TNBC) tumor tropism, serving as a focal point for understanding this aggressive disease. Anchored within the PI3K/ AKT/mTOR signaling axis, PIK3CA mutations exert substantial influence, driving cellular processes that highlight the unique biology of TNBC. This review meticulously highlights the association between PIK3CA mutations and distinct TNBC subtypes, elucidating the gene's multifaceted contributions to tumor tropism. Molecular dissection reveals how PIK3CA mutations dynamically modulate chemokine responses, growth factor signaling, and extracellular matrix interactions, orchestrating the complex migratory behaviour characteristic of TNBC cells. A detailed exploration of PIK3CA-targeted strategies in the therapeutic arena is presented, outlining the current landscape of clinical trials and precision medicine approaches. As the scientific narrative converges, this review underscores the critical role of PIK3CA in shaping the molecular intricacies of TNBC tumor tropism and illuminates pathways toward tailored interventions, promising a paradigm shift in the clinical management of TNBC.
引用
收藏
页数:9
相关论文
共 108 条
  • [1] CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner
    Abdelouahab, Hadjer
    Zhang, Yanyan
    Wittner, Monika
    Oishi, Shinya
    Fujii, Nobutaka
    Besancenot, Rodolphe
    Plo, Isabelle
    Ribrag, Vincent
    Solary, Eric
    Vainchenker, William
    Barosi, Giovanni
    Louache, Fawzia
    [J]. ONCOTARGET, 2017, 8 (33) : 54082 - 54095
  • [2] Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
    Adamo, Barbara
    Deal, Allison M.
    Burrows, Emily
    Geradts, Joseph
    Hamilton, Erika
    Blackwell, Kimberly L.
    Livasy, Chad
    Fritchie, Karen
    Prat, Aleix
    Harrell, J. Chuck
    Ewend, Matthew G.
    Carey, Lisa A.
    Miller, C. Ryan
    Anders, Carey K.
    [J]. BREAST CANCER RESEARCH, 2011, 13 (06)
  • [3] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
    Andre, Fabrice
    Ciruelos, Eva
    Rubovszky, Gabor
    Campone, Mario
    Loibl, Sibylle
    Rugo, Hope S.
    Iwata, Hiroji
    Conte, Pierfranco
    Mayer, Ingrid A.
    Kaufman, Bella
    Yamashita, Toshinari
    Lu, Yen-Shen
    Inoue, Kenichi
    Takahashi, Masato
    Papai, Zsuzsanna
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Hirawat, Samit
    Juric, Dejan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) : 1929 - 1940
  • [4] Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment
    Aponte, Pedro M.
    Caicedo, Andres
    [J]. STEM CELLS INTERNATIONAL, 2017, 2017
  • [5] Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
    Arsenic, Ruza
    Treue, Denise
    Lehmann, Annika
    Hummel, Michael
    Dietel, Manfred
    Denkert, Carsten
    Budczies, Jan
    [J]. BMC CLINICAL PATHOLOGY, 2015, 15
  • [6] PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
    Ascione, Liliana
    Zagami, Paola
    Nicolo, Eleonora
    Crimini, Edoardo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (11):
  • [7] Baranova Anna, 2022, J Med Life, V15, P153, DOI 10.25122/jml-2021-0108
  • [8] Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
    Bareche, Y.
    Venet, D.
    Ignatiadis, M.
    Aftimos, P.
    Piccart, M.
    Rothe, F.
    Sotiriou, C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (04) : 895 - 902
  • [9] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Baselga, Jose
    Im, Seock-Ah
    Iwata, Hiroji
    Cortes, Javier
    De laurentiis, Michele
    Jiang, Zefei
    Arteaga, Carlos L.
    Jonat, Walter
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Takahashi, Masato
    Vuylsteke, Peter
    Hachemi, Soulef
    Dharan, Bharani
    Di Tomaso, Emmanuelle
    Urban, Patrick
    Massacesi, Cristian
    Campone, Mario
    [J]. LANCET ONCOLOGY, 2017, 18 (07) : 904 - 916
  • [10] Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes
    Boyault, Sandrine
    Drouet, Youenn
    Navarro, Claudine
    Bachelot, Thomas
    Lasset, Christine
    Treilleux, Isabelle
    Tabone, Eric
    Puisieux, Alain
    Wang, Qing
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (01) : 29 - 39